Huiqi Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Huiqi Wu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Changbin Qu
Guangzhou National Laboratory, Guangzhou, China
1 shared publicationDongyu Niu
Guangzhou National Laboratory, Guangzhou, China
1 shared publicationHuiyu Chen
State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
1 shared publicationJialing Dai
Guangzhou National Laboratory, Guangzhou, China
1 shared publication- Jialun Shen
Guangzhou National Laboratory, Guangzhou, China
1 shared publication - Jingjing Zou
Guangzhou National Laboratory, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 29 August 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (10) , 3979-4000
A cavity-reduced prefusion RSV F bivalent vaccine elicits durable and protective immunity
Respiratory syncytial virus (RSV) remains a major cause of severe respiratory disease, and stabilization of the prefusion (preF) conformation of the F glycoprotein is central for vaccine development. Here, we report a structure-guided engineering strategy that enhances preF stability by reducing the hydrophobic cavity within the trimeric F protein. Targeted modifications at metastability-associated sites generated RVF-88, a disulfide-free stabilized preF immunogen that preserves key neutralizing epitopes, including antigenic site Ø, while exhibiting improved structural integrity and long-term storage stability. Formulated as an unadjuvanted bivalent vaccine, RVF-88 elicited potent neutralizing antibody responses and durable immune protection lasting up to 5 months in mice. Vaccination also protected both mice and cotton rats against RSV challenge. Structural analyses confirmed the intended cavity-reduction design, revealing a reduced apical hydrophobic cavity volume and surface area while maintaining the prefusion architecture. Together, these findings establish hydrophobic cavity reduction as a rational strategy for stabilizing prefusion RSV F and provide a promising next-generation vaccine candidate with improved stability and immunogenicity for further clinical development.
- 29 August 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (10) , 3979-4000
Open AccessA cavity-reduced prefusion RSV F bivalent vaccine elicits durable and protective immunity
Respiratory syncytial virus (RSV) remains a major cause of severe respiratory disease, and stabilization of the prefusion (preF) conformation of the F glycoprotein is central for vaccine development. Here, we report a structure-guided engineering strategy that enhances preF stability by reducing the hydrophobic cavity within the trimeric F protein. Targeted modifications at metastability-associated sites generated RVF-88, a disulfide-free stabilized preF immunogen that preserves key neutralizing epitopes, including antigenic site Ø, while exhibiting improved structural integrity and long-term storage stability. Formulated as an unadjuvanted bivalent vaccine, RVF-88 elicited potent neutralizing antibody responses and durable immune protection lasting up to 5 months in mice. Vaccination also protected both mice and cotton rats against RSV challenge. Structural analyses confirmed the intended cavity-reduction design, revealing a reduced apical hydrophobic cavity volume and surface area while maintaining the prefusion architecture. Together, these findings establish hydrophobic cavity reduction as a rational strategy for stabilizing prefusion RSV F and provide a promising next-generation vaccine candidate with improved stability and immunogenicity for further clinical development.